GENERAL COMMENTS
The authors present an interesting study protocol outlining their intention to examine the association between the frequency of attacks experienced by gout patients and the use of allopurinol as a urate-lowering therapy. This is an important area of research which requires clarification. As the authors rightly point out, though we know allopurinol reduces serum urate and that the evidence points to a reduction in gout attacks as a result, the evidence to directly support this remain allusive. Below I have provided some comments which may help with the clarity of the manuscript.
Title I'd make reference to allopurinol in the title, this will more accurately depict the purpose of the paper and make it more distinct from other work examining gout attacks Abstract -Methods & analysis • Line 21 -At present this reads like gout attack is the exposure, not the outcome. You've actually defined your cohort as those with gout (using a consultation code), so please amend to reflect this.
• Line 26 -At present, the third sentence makes it sound like you'll be collecting all data every 3-months, rather than just the attack data. Make it clear that all data is collected at baseline, 12 and 24-months, but attack data will be collected every 3-months (as per  your table) .
• Line 28 -Your primary outcome is frequency of gout attack, but what do you mean by frequency, is this mean at 24-months? I think this might be best because initiation of allopurinol can induce attacks, so you may get an artificially high number of attacks early on. It can also take between 6-9 months for number of flares to begin to drop • Line 34 -Your analysis statement could be clearer. Perhaps something to the effect of "Multilevel Poisson regression analysis will be used to examine the association between the number of gout attacks at 24-months(?) experienced by gout patients using allopurinol compared to those gout patients not using this treatment." Sample-size calculation • Page 7, line 21 -I'm unclear how you arrived at n=681 and then state that you'll have a treatment cohort of n=227? Do you expect a response rate of 33%? Also you've not indicated an expected % loss to follow-up, this will be important to when your primary outcome is (i.e. attacks at 12-months or 24-months). Please clarify Data collection and research measures Page 8, line 6 -BMI is calculated using height, not length. This also need correcting in Figure 1 Data analysis Page 9, line 43 -I think "treatment allopurinol" needs to be "allopurinol reatment" 
REVIEWER

GENERAL COMMENTS
The comment in the introduction "Such treatment is controversial, as there is hardly any evidence that it actually reduces the gout attack frequency and/or resolves tophi if present, or prevents long term joint damage" is not accurate. While I acknowledge that RCT evidence is lacking, the body of total evidence supports its use and, as a result, allopurinol treatment is recommended by the ACR/EULAR gout guidelines and the BSR gout guidelines. The lack of evidence does not mean lack of efficacy and therefore, as all clinicians do in clinical practice, have to make decisions based on the best available evidence.
How will the 3 monthly questionnaires be given to patients, posted to them, or during a consultation with the GP, or online, further detail is needed about this and what steps will be taken (in detail) if questionnaires are not filled out by participants.
The use of patient self evaluation for tophi seems very unusual, why not ask GPs to assess for tophi at the baseline visit? This seems to make this assessment highly unreliable.
I cannot comment on the appropriateness or not of the propensity matching statistical methods.
VERSION 1 -AUTHOR RESPONSE
Comments Reviewer 1: Dr James A Prior 1. The authors present an interesting study protocol outlining their intention to examine the association between the frequency of attacks experienced by gout patients and the use of allopurinol as a urate-lowering therapy. This is an important area of research which requires clarification. As the authors rightly point out, though we know allopurinol reduces serum urate and that the evidence points to a reduction in gout attacks as a result, the evidence to directly support this remain allusive. Below I have provided some comments which may help with the clarity of the manuscript.
Answer: Thank you for the compliments.
2. Title I'd make reference to allopurinol in the title, this will more accurately depict the purpose of the paper and make it more distinct from other work examining gout attacks 
Abstract -Methods & analysis
Line 26 -At present, the third sentence makes it sound like you'll be collecting all data every 3-months, rather than just the attack data. Make it clear that all data is collected at baseline, 12 and 24-months, but attack data will be collected every 3-months (as per your 8. Background and rationale Page 5, line 21 -I disagree that gout is often managed with ULT. Despite clear guidelines and benefits, (in the UK) only 30% of patients are prescribed allopurinol and, of those, only 40% have treatment escalated to achieve the target serum urate level<360μmol/L, suggesting that many patients withgout could receive better treatment (Cottrell E, Crabtree V, Edwards JJ, et al. Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Fam Pract 2013). Please amend this sentence to reflect this. Also I wouldn't say this treatment in "controversial", it is recommended by BSR, EULAR & ACR guidelines. However, I do agree there is limited data regarding patient outcomes. Again, please make this sentence clearer 12. Methods -Data collection and research measures Page 8, line 6 -BMI is calculated using height, not length. This also need correcting in Figure  1 Answer: We have amended the text and the figure.
13. Methods -Data analysis Page 9, line 43 -I think "treatment allopurinol" needs to be "allopurinol reatment"
Answer: correct, amended the text.
Comments Reviewer 2: A/Prof Philip Robinson 1. The comment in the introduction "Such treatment is controversial, as there is hardly any evidence that it actually reduces the gout attack frequency and/or resolves tophi if present, or prevents long term joint damage" is not accurate. While I acknowledge that RCT evidence is lacking, the body of total evidence supports its use and, as a result, allopurinol treatment is recommended by the ACR/EULAR gout guidelines and the BSR gout guidelines. The lack of evidence does not mean lack of efficacy and therefore, as all clinicians do in clinical practice, have to make decisions based on the best available evidence.
Answer: You are correct, we formulated this too strongly and have amended the sentence.
2. How will the 3 monthly questionnaires be given to patients, posted to them, or during a consultation with the GP, or online, further detail is neededabout this and what steps will be taken (in detail) if questionnaires are not filled out by participants.
Answer: All questionnaires will be electronically mailed to the patients using GemsTracker (GEneric Medical Survey Tracker) . This is a software package for (complex) 3. The use of patient self evaluation for tophi seems very unusual, why not ask GPs to assess for tophi at the baseline visit? This seems to make this assessment highly unreliable.
